Experiments

Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).

• Activating mutations in ALK provide a therapeutic target in neuroblastoma.

  PMID 18923525 · PMC2587486 · Nature · 2008 · 8 claims · 8 setups

  Full-text index only

  Non-synonymous ALK kinase domain mutations occur in 8% of primary neuroblastomas, with F1174L being the most frequent

  neuroblastoma kelly fish sequencing cytokine-independence

• Targeting Wnt/β-catenin and circadian regulator restores PRC2/EZH2-controlled chromatin bivalency and suppresses cell state diversity.

  PMID 41842971 · PMC13132380 · The Journal of clinical investigation · 2026 · 8 claims · 8 setups

  Full-text index only

  PRC2i/EZH2i alone or combined with AR inhibitors induce diverse cell state programs (CSPs) that increase tumor cell invasion, metastasis, and drug resistance despite only modest suppression of tumor growth.

  lncap pca pdx clinical viability tumor ic50

• Pharmacological perturbation of splicing elicits SMG1 reduction: Implications for cancer therapy.

  PMID 41623476 · PMC12857400 · iScience · 2026 · 7 claims · 12 setups

  Full-text index only

  Splicing-modulatory drugs MS023 and indisulam act as inadvertent NMD inhibitors by downregulating SMG1 protein levels

  4t1 tumor-draining arst panc02 mts tumor ifn-γ

• RUVBL1 and RUVBL2 are druggable MYC effector regulators in neuroblastoma cells.

  PMID 41940329 · PMC13049659 · iScience · 2026 · 8 claims · 8 setups

  Full-text index only

  RUVBL1 and RUVBL2 target gene sets are significantly depleted in MYCN-driven NB mouse tumors treated with ATR inhibitors (elimusertib, ceralasertib)

  th-mycn neuroblastoma clb-bar clb-ga rna-seq gene western

• A novel oxidative stress-related gene signature as an indicator of prognosis and immunotherapy responses in HNSCC.

  PMID 38157249 · PMC10781479 · Aging · 2023 · 7 claims · 8 setups

  Has reproduction · 85

  Consensus clustering of 74 oxidative stress-related genes identifies three distinct HNSCC molecular subgroups (Cluster1-3) with significantly different overall survival and tumor stage distribution

  tcga-hnscc gse41613 gse103322 prjeb23709 bulk single-cell immunohistochemistry

• Novel fatty acid metabolism-related molecular subtyping and prognostic signature for breast cancer.

  PMID 41674979 · PMC12885896 · Translational cancer research · 2026 · 8 claims · 8 setups

  Full-text index only

  A FAM-related gene prognostic model (FAMGM) built using CoxBoost and random survival forest was identified as the optimal model among 101 machine learning combinations, based on highest average C-index across TCGA-BRCA and GSE96058 cohorts

  tcga-brca gse96058 brca breast bulk single-cell spatial

• Nonsense-mediated mRNA decay inhibition reshapes the cancer immunopeptidome.

  PMID 41956098 · PMC7619149 · Immunity · 2026 · 8 claims · 8 setups

  Full-text index only

  Reduced NMD activity (lower NMD score) predicts improved CPI response across >1,000 patients, independent of TMB or tumor type

  tcga a375 reporter patient-derived multi-omics crispr-cas9 sirna

• Radiogenomics predicts immune microenvironment heterogeneity and response to combination immunotherapy in hepatocellular carcinoma.

  PMID 41555384 · PMC12895822 · Journal of translational medicine · 2026 · 8 claims · 8 setups

  Full-text index only

  A parsimonious 2-gene immune-related signature (IRS = 0.425×KPNA2 + 0.302×SMG5) is significantly associated with immune heterogeneity and response to ICI plus anti-angiogenic combination therapy in HCC

  hcc gse202642 paired hcc-derived bulk single-cell immunohistochemistry